StockCIK 1737287

Allogene Therapeutics, Inc. (ALLO): Insider Trades and Fund Holdings

In the past 12 months, Allogene Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 2 sales worth $112K; 0 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$112KSold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 23, 2026.

Recent ALLO insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 23	Oct 21	Geoffrey M. ParkerCFO	CFO	▼ SELL	36,342	1.34	$49K	−3.4%	Form 4 ↗
Aug 25	Aug 21	Earl Martin DouglasGeneral Counsel	General Counsel	▼ SELL	29,697	2.12	$63K	−5.7%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sells	Sold	Latest
Geoffrey M. Parker	CFO	0	$0	1	$49K	Oct 23, 2026
Earl Martin Douglas	General Counsel	0	$0	1	$63K	Aug 25, 2026

Tracked funds that report ALLO

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	3,834,312	$7.98M	0.01%	▲ +79.2%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →